PDCD1 and neoplasm: Simultaneous inhibition of CTLA-4 and PD-1/PD-L1 pathways results in complementary anti-tumor phenomena, and anti-PD-1 combined with anti-CTLA-4 immunosuppressants clearly prolongs the overall survival of patients with advanced NSCLC [240,241].